PNC-27
- Category
- Specialized Research
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
PNC-27 is a synthetic p53-derived peptide marketed as an experimental cancer treatment said to rupture tumor cells while sparing normal ones. The case rests on low-confidence cell and mouse studies (leukemia, ovarian lines), with no human trials and no human safety data. The FDA has warned about contaminated, unapproved versions, and interactions with chemotherapy are unknown. Not an approved drug, it circulates only as unregulated research-grade product.
Read Full recordStudied uses & evidence
Studied uses(7)
Selective cancer cell killing via membrane-bound HDM-2 targeting
LowSelective killing shown in vitro across many cancer types; mechanism defined, no human trials yet.
Transmembrane pore formation causing rapid necrotic cancer cell death
LowCell-culture studies show rapid pore-based cell death within hours; mechanism not yet confirmed independently.
Efficacy against leukemia cells with no harm to normal hematopoietic cells
LowLab and mouse studies show leukemia cell death while sparing normal blood cells; no human trials.
Evidence limits
- Evidence Level
- Preclinical
PNC-27 has strong preclinical data demonstrating selective cancer cell killing through a novel mechanism (binding to membrane-bound HDM-2 and inducing transmembrane pore formation). The mechanism is well-characterized at the structural, biochemical, and cellular levels. In vitro efficacy has been shown in pancreatic cancer, breast cancer, melanoma, multiple leukemia subtypes, colon cancer (including cancer stem cells), patient-derived ovarian cancer (including chemotherapy-resistant lines), and cervical cancer. In vivo results in nude mice show tumor eradication without normal tissue damage. However, translation to humans remains entirely theoretical. No human clinical trials have been conducted, no IND has been filed with the FDA, and the FDA has issued warnings against using PNC-27 products marketed as cancer treatments. The lack of human pharmacokinetics, biodistribution, immunogenicity, and systemic safety data represents a critical gap that must be addressed before clinical application.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(7)
Risks = level of concern: High · Moderate · Low · Theoretical
No established human safety profile
HighFDA warning — contaminated and unapproved products
HighUnregulated product quality from research-grade sources
HighPotential for serious adverse events
ModeratePossible immunogenicity
TheoreticalUnknown interactions with chemotherapy and immunotherapy
ModerateContraindicated in pregnancy, lactation, and severe immune disorders
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.